A new financial year is here, so what better time to consider making some new additions to your portfolio.
Listed below are ten ASX shares that I think could be worth buying in FY 2027.
Image Source: Getty Images
Breville Group Ltd (ASX: BRG)
The first ASX share to consider is Breville, which sells premium kitchen appliances across global markets.
Its coffee machines, cooking products, and food preparation appliances have turned everyday household routines into a strong brand-led growth story. International expansion gives the company a long growth runway.
Goodman Group (ASX: GMG)
Goodman owns and develops industrial property across key global markets.
Its assets are used for logistics, warehousing, ecommerce, and data infrastructure. Demand for well-located industrial space remains strong, and Goodman's data centre development pipeline gives it room to keep creating value.
Macquarie Group Ltd (ASX: MQG)
Macquarie gives investors exposure to global asset management, commodities, markets, banking, and infrastructure-related finance.
Its earnings can move around from year to year, but this ASX share has a strong record of finding opportunities across market cycles.
Megaport Ltd (ASX: MP1)
Megaport provides flexible digital infrastructure through cloud connectivity and its move into compute.
Its Latitude.sh acquisition has broadened the story beyond network-as-a-service. Contract wins in this newer area suggest the ASX share could be building a larger opportunity.
Netwealth Group Ltd (ASX: NWL)
Netwealth operates an investment platform used by financial advisers and wealth professionals.
It has benefited from demand for better technology, reporting, and administration in wealth management. Australia's growing retirement savings pool gives the business a powerful long-term tailwind.
Pro Medicus Ltd (ASX: PME)
Another ASX share to consider is Pro Medicus. It develops medical imaging software for hospitals and radiology groups.
Pro Medicus' Visage platform helps clinicians handle large imaging files quickly across complex healthcare networks. Major contract wins in the United States show the strength of its product and long-term opportunity.
ResMed Inc (ASX: RMD)
ResMed is a global leader in sleep apnoea treatment and connected respiratory care.
Its devices, masks, software, and support services help patients manage long-term breathing conditions. With many sufferers still undiagnosed, the company has a large market opportunity ahead.
TechnologyOne Ltd (ASX: TNE)
TechnologyOne provides enterprise software for governments, universities, and large organisations.
Its software is used for finance, payroll, planning, and administration. The shift to software-as-a-service has strengthened its annual recurring revenue base and could support many more years of growth.
Wesfarmers Ltd (ASX: WES)
Wesfarmers owns a collection of high-quality businesses, including Bunnings, Kmart, Officeworks, and industrial operations.
The company has a long record of disciplined capital allocation. That mix of retail strength, portfolio flexibility, and management quality makes it a dependable blue-chip candidate.
Xero Ltd (ASX: XRO)
Finally, Xero could be an ASX share to buy in FY 2027. It provides cloud accounting software for small businesses and advisers.
The company's platform helps with invoicing, payroll, bank feeds, reporting, and compliance. The company could keep growing as small businesses move more of their financial admin into digital systems.
